Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05846594 | A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer(L1st) | completed | N/A | 463 | Hoffmann-La RocheINDUSTRY | 4 | Dec 17, 2025 | clinicaltrials |
| NCT02314364 | A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC | completed | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02621398 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 23 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02592577 | MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC | completed | Phase 1 | 28 | AdaptimmuneINDUSTRY | 4 | Dec 9, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
| NCT07271446 | An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | completed | Phase 1 | 8 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT03177291 | Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | completed | Phase 1 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03735121 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 438 | Hoffmann-La RocheINDUSTRY | 23 | Dec 5, 2025 | clinicaltrials |
| NCT07267247 | Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer | completed | — | 100 | Taichung Veterans General HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03836066 | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients(TELMA) | completed | Phase 2 | 41 | Fundación GECPOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03926260 | Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA(ELUCID) | completed | N/A | 100 | Centre Hospitalier Departemental VendeeOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05440916 | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer(PRIMM) | completed | Phase 2 | 50 | University Medical Centre MariborOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05664971 | JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 119 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04583046 | Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation | completed | N/A | 78 | Yonsei UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06548451 | Augmented Reality Assisted Lung Nodule Localization: a Multicentered, Prospective, Randomly Controlled, Non-inferiority Trial | completed | N/A | 270 | Shanghai Chest HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT05346380 | Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download | completed | Phase 1 / Phase 2 | 38 | Massachusetts General HospitalOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07250360 | Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC | completed | — | 2,072 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02639026 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | completed | Phase 1 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03132532 | Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03307785 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | completed | Phase 1 | 60 | Tesaro, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04500535 | A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy(LIST) | completed | — | 535 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04614129 | Lung Cancer Risk and Early Detection in Firefighters | completed | N/A | 734 | Massachusetts General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06145750 | Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer(FIRSTLUNG) | completed | N/A | 28 | Delfi Diagnostics Inc.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07243899 | Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy | completed | — | 3,000 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04644237 | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)(DESTINY-LUNG02) | completed | Phase 2 | 152 | Daiichi SankyoINDUSTRY | 10 | Nov 21, 2025 | clinicaltrials |
| NCT05339022 | Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial | completed | N/A | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT05824273 | The INSPIRE-Lung Study | completed | N/A | 512 | Hackensack Meridian HealthOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02197234 | Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC | completed | Phase 1 | 52 | AstraZenecaINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT02606149 | Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life(HIPPOCRATE) | completed | N/A | 123 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05472532 | Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)(INOVOLINE) | completed | N/A | 101 | Hospices Civils de LyonOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT01186861 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 9 | Nov 18, 2025 | clinicaltrials |
| NCT01221077 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | completed | Phase 2 | 88 | Astellas Pharma IncINDUSTRY | 6 | Nov 18, 2025 | clinicaltrials |
| NCT01847209 | Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions | completed | Phase 2 | 25 | Brigham and Women's HospitalOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04895579 | Lung Cancer With Copanlisib and Durvalumab(LCD) | completed | Phase 1 | 11 | Zhonglin HaoOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04068168 | Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)(Imfinzi PMS) | completed | — | 712 | AstraZenecaINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05562895 | A Multicenter Study to Evaluate the Cios Spin and the Ion Endoluminal System for Pulmonary Nodule Biopsy | completed | — | 155 | Intuitive SurgicalINDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT02812667 | Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Lyudmila Bazhenova, M.D.OTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03916419 | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer | completed | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02823990 | TG4010 and Nivolumab in Patients With Lung Cancer | completed | Phase 2 | 13 | Megan Daly, MDOTHER | 1 | Nov 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2025source: clinicaltrials